Thanks to deals signed on Monday alone, another $17 billion is set to change hands in the hyperacquisitive drug business, a single-day record that closes out a bracing quarter for buyouts. But with industry titans paying ever-higher prices for a shrinking number of assets, how long can the good times roll?

…read more

Source: A massive M&A day stokes hopes for more biotech buyouts, but where’s the bottom?


0 No comments